Increasing HPV Vaccination Rates in Residents' Primary Care Clinics

Presenter Information

Normonique Dyer, DO, Thomas Jefferson University HospitalFollow
Amman Bhasin, MD, Thomas Jefferson University HospitalFollow
Abdul Ekiyoyo, MD, Thomas Jefferson UniversityFollow
Umma Fatema, MD, Thomas Jefferson University HospitalFollow
Ilana Goldberg, MD, Thomas Jefferson University HospitalFollow
Chukwuemezie Mamanu, MD, Thomas Jefferson University HospitalFollow
Tamar Wolinsky, MD, Thomas Jefferson University HospitalFollow

Start Date

5-3-2024 9:10 AM

End Date

5-3-2024 11:00 AM

Description

Background

• The human papillomavirus (HPV) vaccine was approved in 2014 for the prevention of anogenital, cervical, and oropharyngeal cancers in female and male adolescents up to 26 years of age^1,2
• Data compiled from multiple clinical trials performed between 2006 and 2018 sought to evaluate benefit from extending the vaccination age given the implications on improving quality of life, morbidity/mortality, and reducing overall healthcare costs for preventable diseases³
• Results showed that increasing the vaccination age up to 45 in both males and females could offer additional protections against high-risk oncogenic strains of the HPV virus3
• Current recommendations from the Advisory Committee for Immunization Practices (ACIP) support shared clinical decision-making when discussing HPV vaccination in adults³
• Despite these updated recommendations, HPV vaccination rates in adults remain low • Several studies have determined that utilizing the electronic health record (EHR) for direct patient outreach leads to increased vaccine administration⁴
• The aim of this study is to investigate potential interventions in Jefferson Primary Care Clinics to increase adult HPV vaccination rates

Keywords

HPV, vaccination, primary care, anogenital cancer, human papillomavirus

Comments

Presented at the 2024 Jefferson Health Equity and Quality Improvement (HEQI) Summit.